Our Library on T Cell-based Immunotherapies for Cancer and Infectious Diseases
HBV
HPV
Cancer
Other
2023
Poster –
ESMO TAT 2023, Poster #36P
Currie S, et al.
Therapeutic Vaccination With HPV-16 Oncoproteins Fused Into a Checkpoint Modifier of Early T-cell Activation Protects Against HPV-associated Tumors in a Preclinical Model2022
Oral –
ID Week 2022, Oral #869
Ertl HCJ, et al.
Novel checkpoint modifier lowers T cell activation threshold and enhances and broadens vaccine-induced responses to chronic viral infectionsPublication –
Front Immunol, DOI: 10.3389/fimmu.2022.985382
Ertl HCJ, et al.
Restricting use of adenovirus vector-based COVID vaccines could endanger public and global healthPublication –
Front Public Health, DOI: 10.3389/fpubh.2022.929445
Ertl HCJ, et al.
Back to the future: Can vaccines win the long-term fight against COVID-19?Oral –
ASGCT, Abstract #0490
Luber A, et al.
Novel Early Checkpoint Modifier Demonstrates Broadened and Enhanced CD8+ T Cell Responses Across Multiple Preclinical StudiesOral –
APASL, Abstract #OP-0685
Hasanpourghadi M, et al.
Preclinical Immunogenicity and Efficacy of VRON-0200: A Novel Therapeutic Vaccine for Potential Functional Cure Therapies in Patients with Chronic HBVPoster –
ESMO TAT, Abstract #143
Luber A, et al.
Checkpoint Modification of BTLA-HVEM-LIGHT Signaling by HSV-1 Glycoprotein D (gD) Improves Vaccine-Induced CD8 T Cell Responses in Pre-clinical Cancer ModelsPublication –
BioRxiv, DOI: 10.1101/2022.02.23.481620
Novikov M, et al.
Pre-clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-22021
Publication –
Virol J, PMID: 34876153
Hasanpourghadi M, et al.
Hepatitis B virus polymerase-specific T cell epitopes shift in a mouse model of chronic infectionOral –
EASL, Abstract #OS-2478
Hasanpourghadi M, et al.
VRON-0200, a Therapeutic HBV Vaccine With an Intrinsic Checkpoint Inhibitor, Elicits Broad CD8+ T Cell Responses and Sustained Antiviral Declines in Preclinical StudiesPublication –
Trends Biochem Sci, PMID: 33810926
Hasanpourghadi M, et al.
COVID-19 Vaccines Based on Adenovirus Vectors2020
Poster –
AASLD, Poster #0826
Hasanpourghadi M, et al.
Glycoprotein D, a Checkpoint Inhibitor of Early T cell Activation, Broadens HBV-specific CD8+ T cell Responses and Produces HBV Viral Load Declines in Preclinical StudiesPoster –
EASL, Poster #1303
Hasanpourghadi M, et al.
Immunogenicity and Efficacy of an HBV Vaccine with an Intrinsic Checkpoint InhibitorPoster –
ASCO-SITC Clinical Immuno-Oncology Symposium, Poster #71
Xiang ZQ, et al.
Glycoprotein D, a Checkpoint Inhibitor of Early T cell Activation, Improves Immunogenicity and Efficacy of an HPV-16 Vaccine in Preclinical Studies2014
Publication –
J Immunol, PMID: 25024391
Zhang Y and Ertl HCJ
The Effect of Adjuvanting Cancer Vaccines with Herpes Simplex Virus Glycoprotein D on Melanoma-Driven CD8+ T Cell Exhaustion